Blog
RSS FeedPosted by Michael Wonder on 07 Aug 2024
Burosumab for the treatment of adults with X-linked hypophosphataemia
7 August 2024 - NICE has issued evidence-based recommendations on the use burosumab (Crysvita) for the treatment of adults X‑linked ...
Posted by Michael Wonder on 06 Aug 2024
Maralixibat chloride for the treatment of patients with cholestatic pruritus associated with Alagille syndrome
31 July 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 04 Aug 2024
How can health technology assessment be improved to optimise access to medicines? Results from a Delphi study in Europe
1 August 2024 - This paper elicited the opinions of European stakeholders on how HTA can be improved to facilitate access. ...
Posted by Michael Wonder on 01 Aug 2024
First targeted treatment made available for hundreds of blood cancer patients on the NHS
1 August 2024 - A take at home tablet which could be a ‘game-changer’ for hundreds of blood cancer patients ...
Posted by Michael Wonder on 30 Jul 2024
NICE disappointed companies unwilling to offer fair price to make Enhertu available for advanced breast cancer
29 July 2024 - Daiichi Sankyo and partner company AstraZeneca have been unwilling to offer a price that would enable NICE ...
Posted by Michael Wonder on 25 Jul 2024
New clot busting drug recommended by NICE set to save NHS millions of pounds
24 July 2024 - Giving a new clot busting drug to people who have had a stroke could help save the ...
Posted by Michael Wonder on 19 Jul 2024
More than 40,000 people could benefit after NICE recommends new ‘take at home’ pill for advanced prostate cancer
19 July 2024 - A new pill to treat advanced hormone sensitive prostate cancer that could benefit just over 40,000 ...
Posted by Michael Wonder on 18 Jul 2024
Rucaparib camsylate for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy
8 July 2024 - The Department of Health and Social Care has asked the NICE to produce guidance on the ...
Posted by Michael Wonder on 18 Jul 2024
Teclistamab for the treatment of patients with relapsed and refractory multiple myeloma after three or more treatments (review of previous guidance)
16 July 2024 - The Department of Health and Social Care has asked the NICE to review the guidance on ...
Posted by Michael Wonder on 16 Jul 2024
Elranatamab for the treatment of patients with relapsed and refractory multiple myeloma after three or more treatments
12 July 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 15 Jul 2024
Clinical benefit, reimbursement outcomes, and prices of FDA approved cancer drugs reviewed through Project Orbis in the USA, Canada, England, and Scotland: a retrospective, comparative analysis
11 July 2024 - Project Orbis is a global initiative that aims to streamline regulatory review processes across international regulators in ...
Posted by Michael Wonder on 10 Jul 2024
NICE recommends Ebglyss (lebrikizumab) for use in moderate to severe atopic dermatitis in the NHS England in eligible adolescents and adults
10 July 2024 - Following approval of the European Commission (October 2023) and the MHRA (December 2023), lebrikizumab will be available ...
Posted by Michael Wonder on 04 Jul 2024
Zilucoplan sodium for the treatment of patients with generalised antibody positive myasthenia gravis
4 July 2024 - The Department of Health and Social Care has asked the NICE to produce guidance on the ...
Posted by Michael Wonder on 03 Jul 2024
Osimertinib mesylate for the adjuvant treatment of patients with EGFR mutation positive non-small-cell lung cancer after complete tumour resection
27 June 2024 - The Department of Health and Social Care has asked the NICE to produce guidance on the ...
Posted by Michael Wonder on 22 Jun 2024
Vertex announces extended long-term reimbursement agreement with NHS England for access to cystic fibrosis medicines Kaftrio, Symkevi and Orkambi
20 June 2024 - Agreement includes access to any future licence extensions. ...